This Asceniv market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
The growth during the historic period can be attributed to the increased demand and adoption rate of the product, higher investments, improved patient access to plasma medications, greater adoption of immunoglobulin products, and the rise in chronic obstructive pulmonary disease cases.
Market growth during the forecast period can be attributed to the increasing prevalence of primary and secondary immunodeficiency, rising demand for available treatments, an expanding number of drugs, the growing prevalence of immunodeficiency diseases, and the increasing need for precision medicine. Key trends in the forecast period include advancements in drug delivery technologies, the rise of digital health technologies, the introduction of advanced treatment options in healthcare, ongoing technological advancements, and product innovation.
The growing prevalence of respiratory diseases is expected to drive the growth of the asceniv market in the future. Respiratory diseases, which affect the lungs and airways, include conditions such as pneumonia, asthma, and chronic obstructive pulmonary disease (COPD). Factors such as air pollution, smoking, climate change, an aging population, and increased exposure to infections contribute to the rise in respiratory diseases. Asceniv works by enhancing the immune system with antibodies, helping individuals with immune deficiencies or viral respiratory conditions fight infections. For example, in December 2023, the National Institutes of Health (NIH) projected that COPD cases would rise to 592 million by 2050, accounting for 9.5% of the eligible population. This increase in respiratory diseases is driving the growth of the asceniv market.
The increasing prevalence of immunodeficiency diseases is expected to boost the growth of the asceniv market. Immunodeficiency diseases refer to conditions where the immune system is unable to effectively fight infections. The rise in these diseases is largely due to improved diagnostic methods, leading to better detection, as well as the aging population. Asceniv helps patients with immunodeficiency diseases by providing concentrated intravenous immunoglobulin therapy that enhances immune function, reduces vulnerability to infections, and supports overall immune health, improving the quality of life for these patients. For example, in June 2024, a report from the Australian Institute of Health and Welfare highlighted that hospitalizations for rheumatoid arthritis had increased by 25% from the previous year. This rising prevalence of immunodeficiency diseases is fueling the growth of the asceniv market.
A key trend in the asceniv market is the adoption of product innovations, such as extended room temperature storage conditions, to improve the product's stability, accessibility, and ease of use. These extended storage conditions allow Asceniv to be stored at room temperature for an extended period without affecting its efficacy or safety. For example, in March 2024, ADMA Biologics, a US-based biotechnology company, received FDA approval for extended room temperature storage conditions for its intravenous immunoglobulin products, ASCENIV and BIVIGAM. These products can now be stored at room temperature (25°C) for up to four weeks during their 36-month shelf life, improving usability and distribution. This advancement facilitates better inventory management and improves access for healthcare providers, especially in areas with limited refrigeration. ASCENIV is used for treating primary humoral immunodeficiency in adults and adolescents, while BIVIGAM is used for various forms of the condition.
The key company operating in the asceniv market is ADMA Biologics Inc.
North America was the largest region in the asceniv market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in asceniv report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the asceniv market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Asceniv is an immunoglobulin (human) injection used to enhance the immune system by providing antibodies to help protect against infections. It is primarily indicated for individuals with primary humoral immunodeficiency (PI), a condition in which the body struggles to produce enough antibodies, leaving individuals more vulnerable to infections.
The main indications for asceniv are primary humoral immunodeficiency and other related conditions. Primary humoral immunodeficiency encompasses a group of rare genetic disorders where the immune system's ability to produce antibodies is impaired. Asceniv is available in both liquid and lyophilized forms, catering to various end users such as hospitals, clinics, and home care settings.
The asceniv market research report is one of a series of new reports that provides asceniv market statistics, including asceniv industry global market size, regional shares, competitors with an asceniv market share, detailed asceniv market segments, market trends and opportunities, and any further data you may need to thrive in the asceniv industry. This asceniv market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The asceniv market consists of sales of products including Gamunex-C, Privigen, Gammagard, Flebogamma, and Octagam. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth during the historic period can be attributed to the increased demand and adoption rate of the product, higher investments, improved patient access to plasma medications, greater adoption of immunoglobulin products, and the rise in chronic obstructive pulmonary disease cases.
Market growth during the forecast period can be attributed to the increasing prevalence of primary and secondary immunodeficiency, rising demand for available treatments, an expanding number of drugs, the growing prevalence of immunodeficiency diseases, and the increasing need for precision medicine. Key trends in the forecast period include advancements in drug delivery technologies, the rise of digital health technologies, the introduction of advanced treatment options in healthcare, ongoing technological advancements, and product innovation.
The growing prevalence of respiratory diseases is expected to drive the growth of the asceniv market in the future. Respiratory diseases, which affect the lungs and airways, include conditions such as pneumonia, asthma, and chronic obstructive pulmonary disease (COPD). Factors such as air pollution, smoking, climate change, an aging population, and increased exposure to infections contribute to the rise in respiratory diseases. Asceniv works by enhancing the immune system with antibodies, helping individuals with immune deficiencies or viral respiratory conditions fight infections. For example, in December 2023, the National Institutes of Health (NIH) projected that COPD cases would rise to 592 million by 2050, accounting for 9.5% of the eligible population. This increase in respiratory diseases is driving the growth of the asceniv market.
The increasing prevalence of immunodeficiency diseases is expected to boost the growth of the asceniv market. Immunodeficiency diseases refer to conditions where the immune system is unable to effectively fight infections. The rise in these diseases is largely due to improved diagnostic methods, leading to better detection, as well as the aging population. Asceniv helps patients with immunodeficiency diseases by providing concentrated intravenous immunoglobulin therapy that enhances immune function, reduces vulnerability to infections, and supports overall immune health, improving the quality of life for these patients. For example, in June 2024, a report from the Australian Institute of Health and Welfare highlighted that hospitalizations for rheumatoid arthritis had increased by 25% from the previous year. This rising prevalence of immunodeficiency diseases is fueling the growth of the asceniv market.
A key trend in the asceniv market is the adoption of product innovations, such as extended room temperature storage conditions, to improve the product's stability, accessibility, and ease of use. These extended storage conditions allow Asceniv to be stored at room temperature for an extended period without affecting its efficacy or safety. For example, in March 2024, ADMA Biologics, a US-based biotechnology company, received FDA approval for extended room temperature storage conditions for its intravenous immunoglobulin products, ASCENIV and BIVIGAM. These products can now be stored at room temperature (25°C) for up to four weeks during their 36-month shelf life, improving usability and distribution. This advancement facilitates better inventory management and improves access for healthcare providers, especially in areas with limited refrigeration. ASCENIV is used for treating primary humoral immunodeficiency in adults and adolescents, while BIVIGAM is used for various forms of the condition.
The key company operating in the asceniv market is ADMA Biologics Inc.
North America was the largest region in the asceniv market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in asceniv report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the asceniv market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Asceniv is an immunoglobulin (human) injection used to enhance the immune system by providing antibodies to help protect against infections. It is primarily indicated for individuals with primary humoral immunodeficiency (PI), a condition in which the body struggles to produce enough antibodies, leaving individuals more vulnerable to infections.
The main indications for asceniv are primary humoral immunodeficiency and other related conditions. Primary humoral immunodeficiency encompasses a group of rare genetic disorders where the immune system's ability to produce antibodies is impaired. Asceniv is available in both liquid and lyophilized forms, catering to various end users such as hospitals, clinics, and home care settings.
The asceniv market research report is one of a series of new reports that provides asceniv market statistics, including asceniv industry global market size, regional shares, competitors with an asceniv market share, detailed asceniv market segments, market trends and opportunities, and any further data you may need to thrive in the asceniv industry. This asceniv market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The asceniv market consists of sales of products including Gamunex-C, Privigen, Gammagard, Flebogamma, and Octagam. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Asceniv Market Characteristics4. Asceniv Market Trends and Strategies5. Asceniv Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Asceniv Pricing Analysis & Forecasts30. Global Asceniv Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Asceniv Market32. Recent Developments in the Asceniv Market
3. Asceniv Market Biologic Drug Characteristics
6. Global Asceniv Growth Analysis and Strategic Analysis Framework
8. Asceniv Market Segmentation
9. Global Asceniv Epidemiology of Clinical Indications
10. Asceniv Market Regional and Country Analysis
11. Asia-Pacific Asceniv Market
12. China Asceniv Market
13. India Asceniv Market
14. Japan Asceniv Market
15. Australia Asceniv Market
16. South Korea Asceniv Market
17. Western Europe Asceniv Market
18. UK Asceniv Market
19. Germany Asceniv Market
20. France Asceniv Market
21. Eastern Europe Asceniv Market
22. North America Asceniv Market
23. USA Asceniv Market
24. Canada Asceniv Market
25. South America Asceniv Market
26. Middle East Asceniv Market
27. Africa Asceniv Market
28. Asceniv Market Competitive Landscape and Company Profiles
29. Global Asceniv Market Pipeline Analysis
33. Asceniv Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Asceniv Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on asceniv market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for asceniv? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The asceniv market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Primary Humoral Immunodeficiency; Other Indications2) by Formulation: Liquid Form; Lyophilized Form
3) by End User: Hospitals; Clinics; Homecare
Key Companies Mentioned: ADMA Biologics Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- ADMA Biologics Inc.
